Karyopharm Therapeutics (KPTI)Officer sold ~$3.3K

~$3.3K

Approx. value · 378 sh @ $8.63

99K

Holds after · shares reported

Traded

Feb 17, 2026

Filed

Feb 19, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Jan 12, 2026Company filing · Form 8-K · Results, Other newsReported its results, and reported other company news
2. Jan 21, 2026InsiderOfficer sold ~$1.6K of KPTI shares in the open market
3. Jan 28, 2026InsiderOfficer sold ~$352 of KPTI shares in the open market
4. Feb 3, 2026InsiderCFO sold ~$10K of KPTI shares in the open market
5. Feb 12, 2026Company filing · Form 8-K · ResultsReported its results
6. Feb 17, 2026 · this disclosureInsiderOfficer sold ~$3.3K of KPTI shares in the open market

What came next

1. Feb 27, 2026Company filing · Form 8-K · Material agreement, Other newsSigned an important agreement, and reported other company news
2. Mar 2, 2026Insider · 6 peopleInsiders: 6 sales (~$294K)
3. Mar 24, 2026Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them (and 2 more items)
4. Apr 21, 2026InsiderOfficer sold ~$4K of KPTI shares in the open market
5. May 14, 2026Company filing · Form 8-K · ResultsReported its results
6. May 14, 2026Insider · 6 peopleInsiders: 6 sales (~$35K)
7. May 21, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“Amendment to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended At th e 2026 Annual Meeting of Stockholders of Karyopharm Therapeutics Inc. (the “Company”) held on May 21, 2026 (the “Annual Meeting”), the Company’s stockholders approved an amendment (the “2022 Plan Amendment”) to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended (the “2022 Plan” and, as further amended by…”

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Karyopharm Therapeutics

For Karyopharm Therapeutics, OQRO holds 3 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its KPTI page.

Other recent filings by Stuart Poulton, EVP, Chief Development Officer

• SEC Form 4 at Karyopharm Therapeutics (KPTI)Jul 30, 2026
• SEC Form 4 at Karyopharm Therapeutics (KPTI)May 15, 2026
• SEC Form 4 at Karyopharm Therapeutics (KPTI)Mar 3, 2026
• SEC Form 4 at Karyopharm Therapeutics (KPTI)Sep 16, 2025
• SEC Form 4 at Karyopharm Therapeutics (KPTI)Jul 30, 2025

The full history of Stuart Poulton, EVP, Chief Development Officer is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Karyopharm Therapeutics

• SEC Schedule 13GOct 8, 2026
• SEC Form 4Oct 2, 2026
• SEC Form 4Sep 2, 2026
• SEC Form 4Jul 30, 2026
• SEC Form 4May 15, 2026
• SEC Form 4May 15, 2026

Everything OQRO holds on this company is on its KPTI page.